Abstract
Natural killer (NK) cell immunotherapies for cancer can complement existing T cell therapies while benefiting from advancements already made in the immunotherapy field. For NK cell manufacturing, induced pluripotent stem cells (iPSCs) offer advantages including eliminating donor variation and providing an ideal platform for genome engineering. At the same time, extracellular vesicles (EVs) have become a major research interest, and purified NK cell extracellular vesicles (NKEVs) have been shown to reproduce the key functions of their parent NK cells. NKEVs have the potential to be developed into a standalone therapeutic with reduced complexity and immunogenicity compared to cell therapies. This review explores the role iPSC technology can play in both NK cell manufacturing and NKEV development.
Introduction
Natural killer (NK) cell adoptive cell transfer (ACT) is emerging as an important cancer immunotherapy. Despite engineered T cell therapies advancing through clinical trials to commercialization (1), some major challenges remain such as high rates of serious adverse side effects, production inefficiencies, and high costs for autologous treatment generation (2). Recent research has shown that NK cells can overcome these challenges to develop into an independent or complementary class of cancer immunotherapies (3–6). A complementary field benefiting from advances in NK cell development is that of NK cell extracellular vesicles (NKEVs), with purified NKEVs having proven to reproduce key functions of their parent NK cells (7).
These developments coincide with induced pluripotent stem cell (iPSC)-derived cell therapies reaching human clinical trials. A particular focus is on iPSC-derived cell products that can be given to patients allogeneically, reducing long-term risks that have slowed translation. iPSC-derived allogeneic cell therapies have the potential to create “off-the-shelf” products, allowing larger batches to be created, reducing costs, and increasing reproducibility. Together, these developments set the scene for iPSC technologies to offer advantages in the manufacture and translation of NK cell-based therapeutics.
NK Cells
NK cells are members of the innate lymphoid family, identified as CD56+CD3-, which provide frontline defense against infections and cancer, and clear damaged cells (8, 9). NK cells are typically classified into two main subpopulations: Cytotoxic CD56dimCD16+ (CD56dim) NK cells account for ~90% of the total NK population, and IFN-γ-producing immunoregulatory CD56brightCD16- (CD56bright) NK cells make up the remaining ~10%(10).
NK cells can discriminate normal from abnormal cells, a process called immune surveillance, via a repertoire of activating and inhibitory receptors (11–13). Direct binding to target cell ligands by a combination of natural cytotoxicity receptor (NCR) family members and NKG2D stimulate NK cell activation and the trafficking of constitutively expressed lytic granules to the site of cell contact and into the target cell (14–16) or the secretion of cytokines (5, 17). Alternatively, CD16 binding alone is sufficient to activate antibody-dependent cellular cytotoxicity (ADCC) (11).
To protect host cells, HLA class I molecules are selectively detected by NK cell inhibitory receptors such as NKG2A and killer immunoglobulin-like receptors (KIRs) (18). Other NK cell inhibitory receptors detect sialic acid, extracellular matrix components, and aminophospholipids, and the expression of immune checkpoints by NK cells, such as CTLA-4 and PD-1, can be stimulated by specific signaling environments (18, 19).
NK cells can be used allogeneically for ACT due to their ability to educate and establish “self-tolerance” to the host HLA class I environment (20). The major sources for NK cell ACT have been peripheral blood (PB-NK) and cord blood (CB-NK), as well as the immortalized line NK-92 (21, 22). Both PB-NK and CB-NK cells are derived from limited donor sources, introducing batch-to-batch variation. NK-92 cells possess anti-cancer potential (23, 24), and have shown efficacy in human clinical trials (25). However, they lack CD16 expression and require irradiation prior to transplantation to inactivate proliferation (26), which in turn impairs therapeutic properties (27, 28). iPSC-derived NK (iPSC-NK) cells have the potential to overcome these limitations while offering additional advantages (29).
Enhancing NK Cell Function
Over time, tumors develop immunosuppressive microenvironment features (30) (Figure 1A) such as altered expressions of receptors and ligands that activate or inhibit NK cells (18, 31, 32), the recruitment of immunomodulatory cells into the tumor mass (33), altered metabolism that results in lower oxygen and increased lactate (34, 35), and the production of inhibitory molecules including TGF-β, IL-10, PGE2, and immune checkpoint proteins such as PD-L1 (32, 36).
Figure 1
Considering these immune evasion mechanisms, various strategies to enhance NK cell function have been developed (4, 37–39). Research into the optimal selection and dosing regimes of cytokines used for expansion and activation (39–42) has identified IL-15 as the preferred choice (43), while work on membrane bound IL-15 and IL-21 has also shown advantages (44–46). Cancers with decreased IL-15 expression correlate with decreased patient survival (47), which led to the development of IL-15 superagonists (48–50) and NK cell modifications that can overcome TGF-β-mediated inhibition of the IL-15 pathway (51, 52).
Another approach has been co-treatment with small molecule immunomodulatory drugs that activate NK cells and increase granzyme-B expression (53, 54) or that increase the expression of NK activating ligands on cancer cells (55, 56). Increased NK cell effects have also been achieved with the combined use of biologics, such as tumor-specific monoclonal antibodies (mAbs) that augment NK cell functions (57–63), or via bi-specific or tri-specific engagers that bind to tumor-specific antigens and NK cells to form immunological synapses (64–67).
Immune checkpoint blockade (ICB) deploying mAbs to block inhibitory pathways has revolutionized our approach to cancer treatment. PD-1/PD-L1 blockade has been shown to increase NK cell cytotoxicity against cancer cells (68–70), and combined treatment of lung cancer patients with allogeneic PB-NK cells and the ICB drug Pembrolizumab increased patient survival (71). Other ICB targets have been identified, and multiple mAbs targeting inhibitory NK cell pathways have reached human clinical trials (72).
Finally, the growing importance of genetic strategies to enhance NK cell function (73), as discussed later, has brought iPSCs to the forefront of NK cell production (29).
Extracellular Vesicles
Extracellular vesicles (EVs), including endosome-derived exosomes (40-150 nm) and plasma membrane-derived microvesicles (50-1000 nm), are lipid nanoparticles secreted by most cell types that are involved in intercellular communication (74). Due to the difficulty determining the biogenesis pathway of individual vesicles, they are classified according to size or density, biochemical composition, or descriptions of conditions of the cell of origin (e.g. "NKEVs") (75).
In recent years EVs have become a major area of research interest. For mesenchymal stem cells (MSCs), it became clear that their immunomodulatory and regenerative functions primarily act through secretory paracrine pathways, including via EVs (76, 77). EVs have the potential to reproduce features of many parent cell therapies while potentially simplifying translational pipelines due to low immunogenicity and inability to replicate (78, 79). Furthermore, progress has been made in EV manufacturing and storage (80–84), critical areas for EV translation.
Mostly using MSC-EVs (85), interventional human clinical trials are active for dystrophic epidermolysis bullosa (NCT04173650), regeneration of macular holes (NCT03437759), acute ischemic stroke (NCT03384433), periodontitis (NCT04270006), craniofacial neuralgia (NCT04202783), inflammatory lung diseases (NCT04388982, NCT04276987), and neurodegenerative diseases (NCT04202770, NCT04388982). T-cell-derived EVs are being investigated for pneumonia (NCT04389385). EVs are also being investigated as liquid biopsy markers for diseases such as cancer (NCT04053855, NCT04523389, NCT04852653, NCT04529915, NCT03228277), diabetes (NCT03106246), neurodegeneration (NCT03944603), and panic disorder (NCT04029740).
Natural Killer Cell Extracellular Vesicles
Although NKEVs have yet to reach clinical trials (85), they have become a significant research focus (7). NKEVs are continuously produced by NK cells and are involved in key mechanisms of NK cell function including immune surveillance, cytotoxicity, and immune modulation (86–90) (Figure 1).
NKEVs express NK markers such as CD56, NKG2D, and cytotoxic effector proteins (e.g. perforin, granzymes A and B, granulysin, and FasL) (86, 87), as well as EV markers Rab5B, CD63, CD81, CD9, and TSG101 (87). Purified NKEVs are cytotoxic against diverse cancer cells (Figure 1B) including hematological cancers (Jurkat, K562, DAUDI) (87), neuroblastoma (CHLA-136) (91), breast carcinoma (MCF-7 (91), MDA-MB-231/F) (92)), ovarian cancer (A2780) (93), and melanoma (B16F10) (94). In mouse glioblastoma xenograft models NKEVs exhibit tumor affinity (92, 95) (Figure 1A).
As well as NK cell effector proteins, NKEVs carry miRNAs that have specific roles in cancer suppression. For example, Sun et al. showed that miR-3607, enriched in purified NKEVs, was required for NK cells to inhibit the malignant transformation of pancreatic cancer cells (Mia PaCa-2, PANC-1) by directly targeting IL-26, suppressing proliferation, migration, and invasion (96). Neviani et al. showed that miR-186 in NKEVs is partially responsible for their cytotoxic effect against neuroblastoma cells (CHLA-136, CHLA-255, and LAN-5) while fortifying other NK cells against the suppressive effect of TGF-β (97) (Figure 1A). NKEVs containing miR-207 have also been shown to reduce neuroinflammation (98).
NKEVs contain immunomodulatory proteins (88, 99, 100) and promote M1 macrophages in a mouse pseudomonas aeruginosa-induced lung injury model (101), reproducing immunomodulatory features of NK cells. Federici et al. reported that NKEVs stimulate CD25 expression on CD3+ T cells, HLA-DR and costimulatory molecule expression on monocytes, and increase the total NK cell population and the CD56dim NK cell fraction in vitro (88) (Figure 1C). Shoae-Hassani et al. showed that NK cells cocultured with neuroblastoma cells (SK-N-SH and CHLA-255) produce NKEVs that confer enhanced neuroblastoma cell cytotoxicity to fresh NK cells (102).
EVs may lack the signaling or metabolic pathways required to respond to inhibitory tumor microenvironment (TME) signals. Accordingly, some groups have shown experimentally that NKEVs retain tumor affinity, tumor suppressive, and immunomodulatory properties in simulated immunosuppressive TMEs using TGF-β, IL-10, and LPS (88, 97). The addition of NKEVs also reduced PD-1 expression on CD3+ T cells even in the presence of TGF-β and IL-10 (88).
Overall, mounting evidence suggests that NKEVs are an integral component of NK cell functions (39, 103), with purified NKEVs demonstrating therapeutic properties (7, 39).
Priming NK Cells for EV Production
NKEVs collected from IL-15-primed NK cells had increased concentration of cytotoxic effectors (92), improved cytolytic activity against cancer cells of glioblastoma, breast cancer, and thyroid cancer, showed improved tumor affinity, and inhibited glioblastoma growth in xenograft mice (92). In NK cells IL-15 regulates the small GTPase Rab27a (92), which was shown in MSCs to increase EV secretion by promoting maturation of endosomal multivesicular bodies (MVBs) containing exosomes (104). Zhu et al. showed similar effects in NK cells with IL-15 priming more than doubling particle number and EV-contained protein (92).
Hypoxic TMEs suppress NK immune surveillance via hypoxia-induced tumor cell shedding of MICA and MICB (105, 106), inhibit NK-mediated cell killing by reducing KIR expression (106), decrease intracellular perforin and granzyme B concentration (107), and reduce degranulation (106). Yet CD16 function is largely maintained, facilitating ADCC (106). To compound this, the NK cell response to the hypoxic TME actually assists blood vessel maturation (108). However, activity of the hypoxia-induced HIF-1α pathway promotes the infiltration of NK cells into tumors and the expression of granzyme B (108). Away from the TME, NK cells cultured in hypoxia for 48 hours produce larger yields of NKEVs with increased total protein, FasL, perforin, and granzyme B concentrations, increased cytotoxicity against breast (MCF-7) and ovarian (A2780) cancer cells in vitro, and increased inhibition of the migration and proliferation of these cancer cells (93). These results are similar to the effects of IL-15 priming, and the two approaches have been shown to be synergistic (109).
Harnessing these NK priming approaches and developing knowledge in this area, as well as more generally into the conditions that maximize NKEV yield and potency, may prove critical in NKEV manufacturing optimization, as seen for other EV sources.
iPSCs in NK Cell Manufacturing
iPSC-derived cell therapies are now featured in many clinical trials, including those using iPSC-NK cells (NCT04106167, NCT03841110) (110). The expansion potential of iPSCs eliminates the need for multiple donors, increasing cell product reproducibility, and epigenetic rejuvenation during iPSC reprogramming erases DNA modifications, producing cells that are biologically young (111–113). This has been shown to cause immune cells to exit exhausted states and adopt phenotypes effective at killing cancer cells (114).
For NK cell-based ACT, chemically defined differentiation protocols have been used to produce iPSC-NK cells with cytotoxicity and immunomodulatory function comparable to primary NK cells (29, 115–117). In cancer patients NK cells are known to undergo functional decline (118–120), similar to that observed in aged patients (121). This decline suggests iPSC-NK cell therapies have advantages, where biologically young, functional cells can replenish the diminished NK cell activity of older and sicker patients.
One of the key advantages of using iPSC technology for cell therapy is its suitability to genome engineering (122). A myriad of genetic NK cell enhancement strategies have been developed to improve targeting and homing to cancer cells, resist immunosuppressive TMEs, and increase cytotoxicity and persistence (73).
For example, deletion in iPSCs of CISH, which encodes the CIS protein, a negative regulator of IL-15, resulted in iPSC-NK cells with better metabolic fitness and increased IL-15 sensitivity (123). Another example is the addition to iPSCs of a cleavage resistant CD16 variant that resulted in enhanced iPSC-NK cells with superior ADCC compared to both unmodified iPSC-NK cells and primary NK cells, and caused comparatively more regression of hematopoietic malignancies and solid tumors when combined with a mAb treatment (124).
Chimeric antigen receptor (CAR)-NK cells, emerging as a key area of cancer immunotherapy development, are also better suited to using iPSC technology. Despite clinical approval of autologous CAR products, allogeneic products avoid patient cell morbidity due to aging or disease and the possible contamination of cancer cells (125). Using iPSC technology has allowed researchers to compare the effectiveness of CAR combinations (116), and two CAR iPSC-NK cell clinical trials are underway (NCT04245722 and jRCT2033200431).
In addition to genome engineering, iPSCs are compatible with synthetic biology. Tumor-derived TGF-β suppression of NK cell cytotoxicity (47) is ameliorated by knocking out TGF-β receptors (51). Intracellularly, TGF-β upregulates miR-27a-5p (126), which if inhibited also increases the cytotoxicity of NK cells (127). Intracellular targets like miR-27a-5p can be targeted by miRNA switches to enhance NK cell function in a context-dependent way. miRNA switches are synthetic mRNAs that can activate the expression of specific miRNAs or proteins in response to endogenous biomolecules (128). Moreover, miRNA switches can be designed to orthogonally, meaning multiple miRNA switches can be combined to tune NK cell cytotoxic and metabolic (129) responses to specific signaling environments. Employed in iPSC-NK cells, this approach could be used to engineer “intelligent” NK cells with programmed context-dependent functions.
iPSCs in NKEV Development
While research on NKEVs has increased, investigations into iPSC-NK cell-derived EVs (iPSC-NKEVs) remain unreported, raising the question of whether iPSC-NK cells also produce EVs (Figure 2). This may represent an important, currently underexplored therapeutic opportunity considering recent research from both NKEVs and EVs from other iPSC-derived cells (130, 131).
Figure 2
Therapeutic properties of iPSC-derived cardiomyocyte- (132–134), neuron- (135), neural stem cell- (136, 137), and MSC- (138–141) EVs, as well as iPSC-EVs (142–144), have already been demonstrated, as has the potential to improve performance for certain applications using bioengineering (145). Using iPSCs as a source for EV production may also help address EV manufacturing and translational challenges such as heterogeneity and scalability (146).
For iPSC-NK cells, Cichocki et al. have shown that they can reproduce key features of NK cells, including dose-dependent cytotoxicity against diverse cancer cells (lung carcinoma (A549), hepatocyte carcinoma (HepG2), ovarian adenocarcinoma (SKOV-3), myeloid leukemia (K562), and melanoma (SK-MEL2)), inflammatory cytokine production, in vivo immunomodulation (including activation and recruitment of circulating T cells), infiltration into solid tumor spheroids in vitro, and the ability to slow tumor progression in vivo (115). Other groups have reported functional iPSC-NK cells (116), and given the documented role of NKEVs in these NK cell processes, these results underline the importance of investigating iPSC-NK cells for EV production.
Similarly to the epigenetic rejuvenation discussed for iPSC-NK cells, Man et al. reported that epigenetic rejuvenation of osteoblast progenitors via histone deacetylase (HDAC) inhibition results in the production of EVs with enhanced function (147). Other studies have shown that, compared to older MSCs, young MSCs produce EVs with better therapeutic properties (148, 149) that are enriched in miRNAs and proteins involved in immunomodulation (148, 150, 151). Interestingly, studies directly comparing therapeutic potential have shown improved efficacy of iPSC-derived MSC-EVs compared to adult donor MSC-EVs in in vitro studies of wound healing (152) and in in vivo disease model studies of osteoarthritis (153). Together, these findings suggest that rejuvenated iPSC-derived cells may be a superior resource for EV manufacturing compared to other sources, although donor age prior to iPSC reprogramming does impact some EV properties (154).
Engineering EVs to increase potency and specificity has already shown promising results in other cell types, and the same principles may translate to NKEVs. Upregulated expression of miRNAs can increase the concentration of miRNAs in EVs, improving therapeutic performance (155–157). Clinical trials are in progress using modified EVs for drug delivery in pancreatic (NCT03608631), colon (NCT01294072), and lung cancer (NCT01159288) (85). While there are yet to be published reports of groups modulating the biochemical composition of NKEVs genetically, the principle of NKEV engineering has been established by Han et al., who used electroporation to load NKEVs with the chemotherapy drug paclitaxel, enhancing their ability to suppress the proliferation and induce the apoptosis of breast cancer cells (158). In MSCs, Böker et al. showed that overexpression of the EV tetraspanin CD9 resulted in increased exosome biogenesis (159), highlighting the role iPSC engineering can play in optimizing production efficiency as well as modulating EV composition.
Conclusion and Future Directions
While the EV industry has moved into a phase of production optimization and human clinical translation, NKEVs are at an earlier stage of development. On the one hand, this means that they can benefit from advancements in purification, storage, and scale-up technologies, but, on the other hand, key translational questions remain relatively unanswered. One question concerns the extent of NKEV heterogeneity, and how this relates to NK cell sub-populations and states. Another concerns the production efficiency of NKEVs, which depends on their potency and yield, and ultimately the number of particles required for effective therapeutic doses. For EVs from other cell types, appropriate doses have been determined (160), and production yields have been documented and linked to manufacturing processes (80, 161). For NK cells, Jong et al. reported that 1-3 x 109 activated NK cells cultured in the G-Rex100 culture system for 48 hours contained ~7 x 107 particles/ml, implying production yields of ~5-14 particles/cell/day (91). Other cell types have been reported to have much higher EV production yields (161). Indeed, Jong et al. compared their NKEV production data to HEK293 (~1841 particles/cell/day) and MSCs (~938 particles/cell/day) (91). Further reports on NKEV production efficiency and detailed investigation of effective therapeutic doses will provide important context to these early numbers. If it is confirmed that iPSC-NK cells secrete NKEVs, then the ability to expand iPSCs to vast numbers before differentiation could be exploited for iPSC-NKEV production.
For NK cell ACT, iPSCs offer advantages in key areas of manufacturing and translation, promising to provide a cell source for biologically young, “off-the-shelf”, and bioengineered enhanced iPSC-NK cells. With iPSCs already making an impact in the clinic, iPSC-NK cells can benefit from advances in manufacturing (162) and genome engineering strategies (163) to create iPSC-NK cells that have context-dependent functions and enhanced potency and specificity. For NKEVs, future work may soon confirm that their composition can be genetically controlled, and, similarly to enhanced NK cells, this could lead to the development of enhanced NKEVs with the potential to be purified as a stand-alone therapeutic or deployed as an addition to engineered iPSC-NK cells that can home to tumor sites and secrete enhanced NKEVs in situ.
Funding
This work was supported by a 2020 Gibon Yeongu Program from the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology(2020R1F1A106727812).
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
NBG, PK and SIK conceptualized the overall paper and NBG drafted the manuscript. NBG primarily researched and structured the EV sections, PK the iPSC-NK cell section, and SIK and DWH the NK cell biology and iPSC-NK sections. NBG and SIK conceptualized the figures. All authors contributed to reviewing and editing, and PK edited the English for the final submission. All authors contributed to the paper and approved the submitted version.
Conflict of interest
NBG is the CSO and a board member of THERABEST Japan, Inc. SIK is the CSO and a board member of THERABEST Co., Ltd and the co-CEO and a board member of THERABEST Japan, Inc. DWH is the CTO and a board member of THERABEST Co., Ltd.
PK declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
SchultzLMackallC. Driving CAR T Cell Translation Forward. Sci Transl Med (2019) 11(481):eaaw2127. doi: 10.1126/scitranslmed.aaw2127
2
GoldensonBHHorPKaufmanDS. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting. Front Immunol (2022) 13. doi: 10.3389/fimmu.2022.841107
3
WendelPReindlLMBexteTKünnemeyerLSärchenVAlbingerNet al. Arming Immune Cells for Battle: A Brief Journey Through the Advancements of T and NK Cell Immunotherapy. Cancers (2021) 13(6):1481. doi: 10.3390/cancers13061481
4
VoglerMShanmugalingamSSärchenVReindlLMGrèzeVBuchingerLet al. Unleashing the Power of NK Cells in Anticancer Immunotherapy. J Mol Med (2022) 100(3):337–49. doi: 10.1007/s00109-021-02120-z
5
ShimasakiNJainACampanaD. NK Cells for Cancer Immunotherapy. Nat Rev Drug Discovery (2020) 19(3):200–18. doi: 10.1038/s41573-019-0052-1
6
ChengMChenYXiaoWSunRTianZ. NK Cell-Based Immunotherapy for Malignant Diseases. Cell Mol Immunol (2013) 10(3):230–52. doi: 10.1038/cmi.2013.10
7
WuFXieMHunMSheZLiCLuoSet al. Natural Killer Cell-Derived Extracellular Vesicles: Novel Players in Cancer Immunotherapy. Front Immunol (2021) 12. doi: 10.3389/fimmu.2021.658698
8
KiesslingRKleinEProssHWigzellH. "Natural" Killer Cells in the Mouse. II. Cytotoxic Cells With Specificity for Mouse Moloney Leukemia Cells. Characteristics of the Killer Cell. Eur J Immunol (1975) 5(2):117–21. doi: 10.1002/eji.1830050209
9
ChanCJSmythMJMartinetL. Molecular Mechanisms of Natural Killer Cell Activation in Response to Cellular Stress. Cell Death Differ (2014) 21(1):5–14. doi: 10.1038/cdd.2013.26
10
CooperMAFehnigerTACaligiuriMA. The Biology of Human Natural Killer-Cell Subsets. Trends Immunol (2001) 22(11):633–40. doi: 10.1016/S1471-4906(01)02060-9
11
MorettaLMorettaA. Unravelling Natural Killer Cell Function: Triggering and Inhibitory Human NK Receptors. EMBO J (2004) 23(2):255–9. doi: 10.1038/sj.emboj.7600019
12
WaldhauerISteinleA. NK Cells and Cancer Immunosurveillance. Oncogene (2008) 27(45):5932–43. doi: 10.1038/onc.2008.267
13
MalmbergKJCarlstenMBjörklundASohlbergEBrycesonYTLjunggrenHG. Natural Killer Cell-Mediated Immunosurveillance of Human Cancer. Semin Immunol (2017) 31:20–9. doi: 10.1016/j.smim.2017.08.002
14
BrycesonYTLjunggrenHGLongEO. Minimal Requirement for Induction of Natural Cytotoxicity and Intersection of Activation Signals by Inhibitory Receptors. Blood (2009) 114(13):2657–66. doi: 10.1182/blood-2009-01-201632
15
BrycesonYTMarchMELjunggrenHGLongEO. Synergy Among Receptors on Resting NK Cells for the Activation of Natural Cytotoxicity and Cytokine Secretion. Blood (2006) 107(1):159–66. doi: 10.1182/blood-2005-04-1351
16
Martínez-LostaoLAnelAPardoJ. How Do Cytotoxic Lymphocytes Kill Cancer Cells? Clin Cancer Res (2015) 21(22):5047–56. doi: 10.1158/1078-0432.CCR-15-0685
17
AbelAMYangCThakarMSMalarkannanS. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol (2018) 9. doi: 10.3389/fimmu.2018.01869
18
SivoriSDella ChiesaMCarlomagnoSQuatriniLMunariEVaccaPet al. Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.02156
19
RussickJJoubertPEGillard-BocquetMTorsetCMeylanMPetitprezFet al. Natural Killer Cells in the Human Lung Tumor Microenvironment Display Immune Inhibitory Functions. J Immunother Cancer (2020) 8(2):e001054. doi: 10.1136/jitc-2020-001054
20
BachanovaVMillerJS. NK Cells in Therapy of Cancer. Crit Rev Oncog (2014) 19(0):133–41. doi: 10.1615/CritRevOncog.2014011091
21
MyersJAMillerJS. Exploring the NK Cell Platform for Cancer Immunotherapy. Nat Rev Clin Oncol (2021) 18(2):85–100. doi: 10.1038/s41571-020-0426-7
22
ShankarKCapitiniCMSahaK. Genome Engineering of Induced Pluripotent Stem Cells to Manufacture Natural Killer Cell Therapies. Stem Cell Res Ther (2020) 11(1):234. doi: 10.1186/s13287-020-01741-4
23
ZhangJZhengHDiaoY. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy. Int J Mol Sci (2019) 20(2):317. doi: 10.3390/ijms20020317
24
KlingemannHBoisselLToneguzzoF. Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line Over Blood NK Cells. Front Immunol (2016) 7:91. doi: 10.3389/fimmu.2016.00091
25
WilliamsBALawADRoutyBdenHollanderNGuptaVWangXHet al. A Phase I Trial of NK-92 Cells for Refractory Hematological Malignancies Relapsing After Autologous Hematopoietic Cell Transplantation Shows Safety and Evidence of Efficacy. Oncotarget (2017) 8(51):89256–68. doi: 10.18632/oncotarget.19204
26
TamYKMartinsonJADoligosaKKlingemannHG. Ex Vivo Expansion of the Highly Cytotoxic Human Natural Killer-92 Cell-Line Under Current Good Manufacturing Practice Conditions for Clinical Adoptive Cellular Immunotherapy. Cytotherapy (2003) 5(3):259–72. doi: 10.1002/eji.1830050209
27
Navarrete-GalvanLGuglielmoMCruz AmayaJSmith-GagenJLombardiVCMericaRet al. Optimizing NK-92 Serial Killers: Gamma Irradiation, CD95/Fas-Ligation, and NK or LAK Attack Limit Cytotoxic Efficacy. J Transl Med (2022) 20(1):151. doi: 10.1186/s12967-022-03350-6
28
WalcherLKistenmacherAKSommerCBöhlenSZiemannCDehmelSet al. Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing. Front Immunol (2021) 12. doi: 10.3389/fimmu.2021.684052
29
KaragiannisPKimSI. iPSC-Derived Natural Killer Cells for Cancer Immunotherapy. Mol Cells (2021) 44(8):541–8. doi: 10.14348/molcells.2021.0078
30
KawemeNMZhouF. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment. Front Immunol (2021) 12:2348. doi: 10.3389/fimmu.2021.683381
31
Dianat-MoghadamHRokniMMarofiFPanahiYYousefiM. Natural Killer Cell–Based Immunotherapy: From Transplantation Toward Targeting Cancer Stem Cells. J Cell Physiol (2019) 234(1):259–73. doi: 10.1002/jcp.26878
32
GrothAKlössSvon StrandmannEPKoehlUKochJ. Mechanisms of Tumor and Viral Immune Escape From Natural Killer Cell-Mediated Surveillance. J Innate Immun (2011) 3(4):344–54. doi: 10.1159/000327014
33
VinayDSRyanEPPawelecGTalibWHStaggJElkordEet al. Immune Evasion in Cancer: Mechanistic Basis and Therapeutic Strategies. Semin Cancer Biol (2015) 35:S185–98. doi: 10.1016/j.semcancer.2015.03.004
34
Cruz-BermúdezALaza-BriviescaRCasarrubiosMSierra-RoderoBProvencioM. The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy. Biomedicines (2021) 9(4):361. doi: 10.3390/biomedicines9040361
35
XiaLOyangLLinJTanSHanYWuNet al. The Cancer Metabolic Reprogramming and Immune Response. Mol Cancer (2021) 20(1):28. doi: 10.1186/s12943-021-01316-8
36
ParkALeeYKimMSKangYJParkYJJungHet al. Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation. Front Immunol (2018) 9:1859. doi: 10.3389/fimmu.2018.01859
37
ReindlLMAlbingerNBexteTMüllerSHartmannJUllrichE. Immunotherapy With NK Cells: Recent Developments in Gene Modification Open Up New Avenues. OncoImmunology (2020) 9(1):1777651. doi: 10.1080/2162402X.2020.1777651
38
VillalbaMAlexiaCBellin-RobertAFayd’herbe de MaudaveAGitenayD. Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells. Front Immunol (2020) 10:3026. doi: 10.3389
39
HuWWangGHuangDSuiMXuY. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. Front Immunol (2019) 10:1205. doi: 10.3389/fimmu.2019.01205
40
FelicesMLenvikAJMcElmurryRChuSHinderliePBendzickLet al. Continuous Treatment With IL-15 Exhausts Human NK Cells via a Metabolic Defect. JCI Insight (2018) 3(3):e96219. doi: 10.1172/jci.insight.96219
41
WuYTianZWeiH. Developmental and Functional Control of Natural Killer Cells by Cytokines. Front Immunol (2017) 8. doi: 10.3389/fimmu.2017.00930
42
RomeeRRosarioMBerrien-ElliottMMWagnerJAJewellBASchappeTet al. Cytokine-Induced Memory-Like Natural Killer Cells Exhibit Enhanced Responses Against Myeloid Leukemia. Sci Transl Med (2016) 8(357):357ra123–357ra123. doi: 10.1126/scitranslmed.aaf2341
43
MillerJSLanierLL. Natural Killer Cells in Cancer Immunotherapy. Annu Rev Cancer Biol (2019) 3(1):77–103. doi: 10.1146/annurev-cancerbio-030518-055653
44
ImamuraMShookDKamiyaTShimasakiNChaiSMHCoustan-SmithEet al. Autonomous Growth and Increased Cytotoxicity of Natural Killer Cells Expressing Membrane-Bound Interleukin-15. Blood (2014) 124(7):1081–8. doi: 10.1182/blood-2014-02-556837
45
OyerJLPandeyVIgarashiRYSomanchiSSZakariASolhMet al. Natural Killer Cells Stimulated With PM21 Particles Expand and Biodistribute In Vivo: Clinical Implications for Cancer Treatment. Cytotherapy (2016) 18(5):653–63. doi: 10.1016/j.jcyt.2016.02.006
46
DenmanCJSenyukovVVSomanchiSSPhatarpekarPVKoppLMJohnsonJLet al. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. PloS One (2012) 7(1):e30264. doi: 10.1371/journal.pone.0030264
47
MlecnikBBindeaGAngellHKSassoMSObenaufACFredriksenTet al. Functional Network Pipeline Reveals Genetic Determinants Associated With in Situ Lymphocyte Proliferation and Survival of Cancer Patients. Sci Transl Med (2014) 6(228):228ra37–228ra37. doi: 10.1126/scitranslmed.3007240
48
WrangleJMVelchetiVPatelMRGarrett-MayerEHillEGRavenelJGet al. ALT-803, an IL-15 Superagonist, in Combination With Nivolumab in Patients With Metastatic non-Small Cell Lung Cancer: A non-Randomised, Open-Label, Phase 1b Trial. Lancet Oncol (2018) 19(5):694–704. doi: 10.1016/S1470-2045(18)30148-7
49
RomeeRCooleySBerrien-ElliottMMWesterveltPVernerisMRWagnerJEet al. First-In-Human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse After Transplantation. Blood (2018) 131(23):2515–27. doi: 10.1182/blood-2017-12-823757
50
KnudsonKMHodgeJWSchlomJGameiroSR. Rationale for IL-15 Superagonists in Cancer Immunotherapy. Expert Opin Biol Ther (2020) 20(7):705–9. doi: 10.1080/14712598.2020.1738379
51
YvonESBurgaRPowellACruzCRFernandesRBareseCet al. Cord Blood Natural Killer Cells Expressing a Dominant Negative TGF-β Receptor: Implications for Adoptive Immunotherapy for Glioblastoma. Cytotherapy (2017) 19(3):408–18. doi: 10.1016/j.jcyt.2016.12.005
52
WilsonEBEl-JawhariJJNeilsonALHallGDMelcherAAMeadeJLet al. Human Tumour Immune Evasion via TGF-β Blocks NK Cell Activation But Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity. PloS One (2011) 6(9):e22842. doi: 10.1371/journal.pone.0022842
53
HideshimaTOgiyaDLiuJHaradaTKurataKBaeJet al. Immunomodulatory Drugs Activate NK Cells via Both Zap-70 and Cereblon-Dependent Pathways. Leukemia (2021) 35(1):177–88. doi: 10.1038/s41375-020-0809-x
54
HayashiTHideshimaTAkiyamaMPodarKYasuiHRajeNet al. Molecular Mechanisms Whereby Immunomodulatory Drugs Activate Natural Killer Cells: Clinical Application. Br J Haematol (2005) 128(2):192–203. doi: 10.1111/j.1365-2141.2004.05286.x
55
Le RoyAPrébetTCastellanoRGoubardARiccardiFFauriatCet al. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Front Immunol (2018) 9. doi: 10.3389/fimmu.2018.00977
56
FiondaCAbruzzeseMPZingoniACecereFVulpisEPeruzziGet al. The IMiDs Targets IKZF-1/3 and IRF4 as Novel Negative Regulators of NK Cell-Activating Ligands Expression in Multiple Myeloma. Oncotarget (2015) 6(27):23609–30. doi: 10.18632/oncotarget.4603
57
RodaJMJoshiTButcharJPMcAleesJWLehmanATridandapaniSet al. The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor Positive Tumor Cells is Enhanced by Cytokines. Clin Cancer Res Off J Am Assoc Cancer Res (2007) 13(21):6419–28. doi: 10.1158/1078-0432.CCR-07-0865
58
BeanoASignorinoEEvangelistaABrusaDMistrangeloMPolimeniMAet al. Correlation Between NK Function and Response to Trastuzumab in Metastatic Breast Cancer Patients. J Transl Med (2008) 6:25. doi: 10.1186/1479-5876-6-25
59
WuLAdamsMCarterTChenRMullerGStirlingDet al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells. Clin Cancer Res Off J Am Assoc Cancer Res (2008) 14(14):4650–7. doi: 10.1158/1078-0432.CCR-07-4405
60
VarchettaSGibelliNOlivieroBNardiniEGennariRGattiGet al. Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2. Cancer Res (2007) 67(24):11991–9. doi: 10.1158/0008-5472.CAN-07-2068
61
KoernerSPAndréMCLeiboldJSKousisPCKüblerAPalMet al. An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia. Leukemia (2017) 31(2):459–69. doi: 10.1038/leu.2016.194
62
KimYMParkJSKimSKJungKMHwangYSHanMet al. The Transgenic Chicken Derived Anti-CD20 Monoclonal Antibodies Exhibits Greater Anti-Cancer Therapeutic Potential With Enhanced Fc Effector Functions. Biomaterials (2018) 167:58–68. doi: 10.1016/j.biomaterials.2018.03.021
63
Ferrari de AndradeLTayREPanDLuomaAMItoYBadrinathSet al. Antibody-Mediated Inhibition of MICA and MICB Shedding Promotes NK Cell–Driven Tumor Immunity. Science (2018) 359(6383):1537–42. doi: 10.1126/science.aao0505
64
GauthierLMorelAAncerizNRossiBBlanchard-AlvarezAGrondinGet al. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity. Cell (2019) 177(7):1701–1713.e16. doi: 10.1016/j.cell.2019.04.041
65
FelicesMLenvikTRDavisZBMillerJSValleraDA. Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. Methods Mol Biol Clifton NJ (2016) 1441:333–46. doi: 10.1007/978-1-4939-3684-7_28
66
KellnerCBruenkeJHornerHSchubertJSchwenkertMMentzKet al. Heterodimeric Bispecific Antibody-Derivatives Against CD19 and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against B-Lymphoid Tumor Cells. Cancer Lett (2011) 303(2):128–39. doi: 10.1016/j.canlet.2011.01.020
67
BruenkeJBarbinKKunertSLangPPfeifferMStieglmaierKet al. Effective Lysis of Lymphoma Cells With a Stabilised Bispecific Single-Chain Fv Antibody Against CD19 and Fcγriii (Cd16). Br J Haematol (2005) 130(2):218–28. doi: 10.1111/j.1365-2141.2005.05414.x
68
PesceSGreppiMGrossiFDel ZottoGMorettaLSivoriSet al. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells. Front Immunol (2019) 10. doi: 10.3389/fimmu.2019.01242
69
HsuJHodginsJJMaratheMNicolaiCJBourgeois-DaigneaultMCTrevinoTNet al. Contribution of NK Cells to Immunotherapy Mediated by PD-1/PD-L1 Blockade. J Clin Invest (2018) 128(10):4654–68. doi: 10.1172/JCI99317
70
JuliáEPAmanteAPampenaMBMordohJLevyEM. Avelumab, an IgG1 Anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Front Immunol (2018) 9. doi: 10.3389/fimmu.2018.02140
71
LinMLuoHLiangSChenJLiuANiuLet al. Pembrolizumab Plus Allogeneic NK Cells in Advanced non–Small Cell Lung Cancer Patients. J Clin Invest (2020) 130(5):2560–9. doi: 10.1172/JCI132712
72
PoggiAZocchiMR. Natural Killer Cells and Immune-Checkpoint Inhibitor Therapy: Current Knowledge and New Challenges. Mol Ther - Oncolytics (2022) 24:26–42. doi: 10.1016/j.omto.2021.11.016
73
MantessoSGeertsDSpanholtzJKučerováL. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.607131
74
WiklanderOPBBrennanMÁLötvallJBreakefieldXOEL AndaloussiS. Advances in Therapeutic Applications of Extracellular Vesicles. Sci Transl Med (2019) 11(492):eaav8521. doi: 10.1126/scitranslmed.aav8521
75
ThéryCWitwerKWAikawaEAlcarazMJAndersonJDAndriantsitohainaRet al. Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines. J Extracell Vesicles (2018) 7(1):1535750. doi: 10.1080/20013078.2018.1535750
76
LaiRCYeoRWYLimSK. Mesenchymal Stem Cell Exosomes. Semin Cell Dev Biol (2015) 40:82–8. doi: 10.1016/j.semcdb.2015.03.001
77
TanTTTohWSLaiRCLimSK. Practical Considerations in Transforming MSC Therapy for Neurological Diseases From Cell to EV. Exp Neurol (2022) 349:113953. doi: 10.1016/j.expneurol.2021.113953
78
KenjoEHozumiHMakitaYIwabuchiKAFujimotoNMatsumotoSet al. Low Immunogenicity of LNP Allows Repeated Administrations of CRISPR-Cas9 mRNA Into Skeletal Muscle in Mice. Nat Commun (2021) 12(1):1–13. doi: 10.1038/s41467-021-26714-w
79
LaiRCArslanFLeeMMSzeNSKChooAChenTSet al. Exosome Secreted by MSC Reduces Myocardial Ischemia/Reperfusion Injury. Stem Cell Res (2010) 4(3):214–22. doi: 10.1016/j.scr.2009.12.003
80
PaganiniCPalmieroUCPocsfalviGTouzetNBongiovanniAArosioP. Scalable Production and Isolation of Extracellular Vesicles: Available Sources and Lessons From Current Industrial Bioprocesses. Biotechnol J (2019) 14(10):1800528. doi: 10.1002/biot.201800528
81
AdlerzKPatelDRowleyJNgKAhsanT. Strategies for Scalable Manufacturing and Translation of MSC-Derived Extracellular Vesicles. Stem Cell Res (2020) 48:101978. doi: 10.1016/j.scr.2020.101978
82
NgKSSmithJAMcAteerMPMeadBEWareJJacksonFOet al. Bioprocess Decision Support Tool for Scalable Manufacture of Extracellular Vesicles. Biotechnol Bioeng (2019) 116(2):307–19. doi: 10.1002/bit.26809
83
Marquez-CurtisLAJanowska-WieczorekAMcGannLEElliottJAW. Mesenchymal Stromal Cells Derived From Various Tissues: Biological, Clinical and Cryopreservation Aspects. Cryobiology (2015) 71(2):181–97. doi: 10.1016/j.cryobiol.2015.07.003
84
ZhangYBiJHuangJTangYDuSLiP. Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications. Int J Nanomed (2020) 15:6917. doi: 10.2147/IJN.S264498
85
HerrmannIKWoodMJAFuhrmannG. Extracellular Vesicles as a Next-Generation Drug Delivery Platform. Nat Nanotechnol (2021) 16(7):748–59. doi: 10.1038/s41565-021-00931-2
86
WuCHLiJLiLSunJFabbriMWayneASet al. Extracellular Vesicles Derived From Natural Killer Cells Use Multiple Cytotoxic Proteins and Killing Mechanisms to Target Cancer Cells. J Extracell Vesicles (2019) 8(1):1588538. doi: 10.1080/20013078.2019.1588538
87
LuginiLCecchettiSHuberVLucianiFMacchiaGSpadaroFet al. Immune Surveillance Properties of Human NK Cell-Derived Exosomes. J Immunol (2012) 189(6):2833–42. doi: 10.4049/jimmunol.1101988
88
FedericiCShahajECecchettiSCameriniSCasellaMIessiEet al. Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors. Front Immunol (2020) 11:262. doi: 10.3389/fimmu.2020.00262
89
VecchioFDMartinez-RodriguezVSchukkingMCocksABroseghiniEFabbriM. Professional Killers: The Role of Extracellular Vesicles in the Reciprocal Interactions Between Natural Killer, CD8+ Cytotoxic T-Cells and Tumour Cells. J Extracell Vesicles (2021) 10(6):e12075. doi: 10.1002/jev2.12075
90
LiCDonningerHEatonJYaddanapudiK. Regulatory Role of Immune Cell-Derived Extracellular Vesicles in Cancer: The Message Is in the Envelope. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.01525
91
JongAYWuCHLiJSunJFabbriMWayneASet al. Large-Scale Isolation and Cytotoxicity of Extracellular Vesicles Derived From Activated Human Natural Killer Cells. J Extracell Vesicles (2017) 6(1):1294368. doi: 10.1080/20013078.2017.1294368
92
ZhuLKalimuthuSOhJMGangadaranPBaekSHJeongSYet al. Enhancement of Antitumor Potency of Extracellular Vesicles Derived From Natural Killer Cells by IL-15 Priming. Biomaterials (2019) 190–191:38–50. doi: 10.1016/j.biomaterials.2018.10.034
93
JiangYJiangHWangKLiuCManXFuQ. Hypoxia Enhances the Production and Antitumor Effect of Exosomes Derived From Natural Killer Cells. Ann Transl Med (2021) 9(6):473–3. doi: 10.21037/atm-21-347
94
ZhuLKalimuthuSGangadaranPOhJMLeeHWBaekSHet al. Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma. Theranostics (2017) 7(10):2732–45. doi: 10.7150/thno.18752
95
WangGHuWChenHShouXYeTXuY. Cocktail Strategy Based on NK Cell-Derived Exosomes and Their Biomimetic Nanoparticles for Dual Tumor Therapy. Cancers (2019) 11(10):1560. doi: 10.3390/cancers11101560
96
SunHShiKQiKKongHZhangJDaiSet al. Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26. Front Immunol (2019) 10:2819. doi: 10.3389/fimmu.2019.02819
97
NevianiPWisePMMurtadhaMLiuCWWuCHJongAYet al. Natural Killer–Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms. Cancer Res (2019) 79(6):1151–64. doi: 10.1158/0008-5472.CAN-18-0779
98
LiDWangYJinXHuDXiaCXuHet al. NK Cell-Derived Exosomes Carry miR-207 and Alleviate Depression-Like Symptoms in Mice. J Neuroinflamm (2020) 17(1):1–19. doi: 10.1186/s12974-020-01787-4
99
ChoiJWLimSKangJHHwangSHHwangKCKimSWet al. Proteome Analysis of Human Natural Killer Cell Derived Extracellular Vesicles for Identification of Anticancer Effectors. Molecules (2020) 25(21):5216. doi: 10.3390/molecules25215216
100
KorenevskiiAVMilyutinaYZhdanovaAAPyatyginaKMSokolovDISel’kovSA. Mass-Spectrometric Analysis of Proteome of Microvesicles Produced by NK-92 Natural Killer Cells. Bull Exp Biol Med (2018) 165(4):564–71. doi: 10.1007/s10517-018-4214-7
101
JiaRCuiKLiZGaoYZhangBWangZet al. NK Cell-Derived Exosomes Improved Lung Injury in Mouse Model of Pseudomonas Aeruginosa Lung Infection. J Physiol Sci (2020) 70(1):50. doi: 10.1186/s12576-020-00776-9
102
Shoae-HassaniAHamidiehAABehfarMMohseniRMortazavi-TabatabaeiSAAsgharzadehS. NK Cell-Derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-Activated NK Cells. J Immunother (2017) 40(7):265–76. doi: 10.1097/CJI.0000000000000179
103
ShaverKACroom-PerezTJCopikAJ. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy. Front Immunol (2021) 12:679117. doi: 10.3389/fimmu.2021.679117
104
WangJBonacquistiEEBrownADNguyenJ. Boosting the Biogenesis and Secretion of Mesenchymal Stem Cell-Derived Exosomes. Cells (2020) 9(3):660. doi: 10.3390/cells9030660
105
SiemensDRHuNSheikhiAKChungEFrederiksenLJProssHet al. Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide. Cancer Res (2008) 68(12):4746–53. doi: 10.1158/0008-5472.CAN-08-0054
106
BalsamoMManziniCPietraGRaggiFBlengioFMingariMCet al. Hypoxia Downregulates the Expression of Activating Receptors Involved in NK-Cell-Mediated Target Cell Killing Without Affecting ADCC. Eur J Immunol (2013) 43(10):2756–64. doi: 10.1002/eji.201343448
107
SarkarSGermeraadWTVRouschopKMASteeghsEMPvan GelderMBosGMJet al. Hypoxia Induced Impairment of NK Cell Cytotoxicity Against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells. PloS One (2013) 8(5):e64835. doi: 10.1371/journal.pone.0064835
108
KrzywinskaEKantari-MimounCKerdilesYSobeckiMIsagawaTGotthardtDet al. Loss of HIF-1α in Natural Killer Cells Inhibits Tumour Growth by Stimulating non-Productive Angiogenesis. Nat Commun (2017) 8(1):1–13. doi: 10.1038/s41467-017-01599-w
109
VelásquezSYKillianDSchulteJStichtCThielMLindnerHA. Short Term Hypoxia Synergizes With Interleukin 15 Priming in Driving Glycolytic Gene Transcription and Supports Human Natural Killer Cell Activities *. J Biol Chem (2016) 291(25):12960–77. doi: 10.1074/jbc.M116.721753
110
YamanakaS. Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges. Cell Stem Cell (2020) 27(4):523–31. doi: 10.1016/j.stem.2020.09.014
111
TakahashiKYamanakaS. Induction of Pluripotent Stem Cells From Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. (2006) 126(4):663–76. doi: 10.1016/j.cell.2006.07.024
112
TakahashiKTanabeKOhnukiMNaritaMIchisakaTTomodaKet al. Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors. Cell. (2007) 131(5):861–72. doi: 10.1016/j.cell.2007.11.019
113
MaheraliNSridharanRXieWUtikalJEminliSArnoldKet al. Directly Reprogrammed Fibroblasts Show Global Epigenetic Remodeling and Widespread Tissue Contribution. Cell Stem Cell (2007) 1(1):55–70. doi: 10.1016/j.stem.2007.05.014
114
KaragiannisPIriguchiSKanekoS. Reprogramming Away From the Exhausted T Cell State. Semin Immunol (2016) 28(1):35–44. doi: 10.1016/j.smim.2015.10.007
115
CichockiFBjordahlRGaidarovaSMahmoodSAbujarourRWangHet al. iPSC-Derived NK Cells Maintain High Cytotoxicity and Enhance In Vivo Tumor Control in Concert With T Cells and Anti–PD-1 Therapy. Sci Transl Med (2020) 12(568):eaaz5618. doi: 10.1126/scitranslmed.aaz5618
116
LiYHermansonDLMoriarityBSKaufmanDS. Human iPSC-Derived Natural Killer Cells Engineered With Chimeric Antigen Receptors Enhance Anti-Tumor Activity. Cell Stem Cell (2018) 23(2):181–192.e5. doi: 10.1016/j.stem.2018.06.002
117
LupoKBMoonJIChambersAMMatosevicS. Differentiation of Natural Killer Cells From Induced Pluripotent Stem Cells Under Defined, Serum- and Feeder-Free Conditions. Cytotherapy (2021) 23(10):939–52. doi: 10.1016/j.jcyt.2021.05.001
118
CerwenkaALanierLL. Natural Killer Cell Memory in Infection, Inflammation and Cancer. Nat Rev Immunol (2016) 16(2):112–23. doi: 10.1038/nri.2015.9
119
JudgeSJMurphyWJCanterRJ. Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. Front Cell Infect Microbiol (2020) 10:49. doi: 10.3389/fcimb.2020.00049
120
RoccaYSRobertiMPArriagaJMAmatMBrunoLPampenaMBet al. Altered Phenotype in Peripheral Blood and Tumor-Associated NK Cells From Colorectal Cancer Patients. Innate Immun (2013) 19(1):76–85. doi: 10.1177/1753425912453187
121
HazeldineJLordJM. The Impact of Ageing on Natural Killer Cell Function and Potential Consequences for Health in Older Adults. Ageing Res Rev (2013) 12(4):1069–78. doi: 10.1016/j.arr.2013.04.003
122
WoltjenKOceguera-YanezFKagawaHKimSI. At the Conflux of Human Genome Engineering and Induced Pluripotency. In: TurksenK, editor. Genome Editing. Cham: Springer International Publishing (2016). p. 45–64.
123
ZhuHBlumRHBernareggiDAskEHWuZHoelHJet al. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-Tumor Activity. Cell Stem Cell (2020) 27(2):224–237.e6. doi: 10.1016/j.stem.2020.05.008
124
ZhuHBlumRHBjordahlRGaidarovaSRogersPLeeTTet al. Pluripotent Stem Cell–Derived NK Cells With High-Affinity Noncleavable CD16a Mediate Improved Antitumor Activity. Blood (2020) 135(6):399–410. doi: 10.1182/blood.2019000621
125
RuellaMXuJBarrettDMFraiettaJAReichTJAmbroseDEet al. Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell. Nat Med (2018) 24(10):1499–503. doi: 10.1038/s41591-018-0201-9
126
RegisSCaliendoFDonderoACasuBRomanoFLoiaconoFet al. TGF-β1 Downregulates the Expression of CX3CR1 by Inducing miR-27a-5p in Primary Human NK Cells. Front Immunol (2017) 25(8):868. doi: 10.3389/fimmu.2017.00868
127
KimTDLeeSUYunSSunHNLeeSHKimJWet al. Human microRNA-27a* Targets Prf1 and GzmB Expression to Regulate NK-Cell Cytotoxicity. Blood (2011) 118(20):5476–86. doi: 10.1182/blood-2011-04-347526
128
FujitaYHirosawaMHayashiKHataniTYoshidaYYamamotoTet al. A Versatile and Robust Cell Purification System With an RNA-Only Circuit Composed of microRNA-Responsive ON and OFF Switches. Sci Adv (2022) 8(1):eabj1793. doi: 10.1126/sciadv.abj1793
129
CichockiFWuCYZhangBFelicesMTesiBTuiningaKet al. ARID5B Regulates Metabolic Programming in Human Adaptive NK Cells. J Exp Med (2018) 215(9):2379–95. doi: 10.1084/jem.20172168
130
WangAYL. Human Induced Pluripotent Stem Cell-Derived Exosomes as a New Therapeutic Strategy for Various Diseases. Int J Mol Sci (2021) 22(4):1769. doi: 10.3390/ijms22041769
131
TaheriBSoleimaniMFekri AvalSEsmaeiliEBaziZZarghamiN. Induced Pluripotent Stem Cell-Derived Extracellular Vesicles: A Novel Approach for Cell-Free Regenerative Medicine. J Cell Physiol (2019) 234(6):8455–64. doi: 10.1002/jcp.27775
132
SantosoMRIkedaGTadaYJungJHVaskovaESierraRGet al. Exosomes From Induced Pluripotent Stem Cell-Derived Cardiomyocytes Promote Autophagy for Myocardial Repair. J Am Heart Assoc (2020) 9(6):e014345. doi: 10.1161/JAHA.119.014345
133
GaoLWangLWeiYKrishnamurthyPWalcottGPMenaschéPet al. Exosomes Secreted by hiPSC-Derived Cardiac Cells Improve Recovery From Myocardial Infarction in Swine. Sci Transl Med (2020) 12(561):eaay1318. doi: 10.1126/scitranslmed.aay1318
134
El HaraneNKervadecABellamyVPidialLNeametallaHJPerierMCet al. Acellular Therapeutic Approach for Heart Failure: In Vitro Production of Extracellular Vesicles From Human Cardiovascular Progenitors. Eur Heart J (2018) 39(20):1835–47. doi: 10.1093/eurheartj/ehy012
135
HicksDAJonesACCorbettNJFisherKPickering-BrownSMAsheMPet al. Extracellular Vesicles Isolated From Human Induced Pluripotent Stem Cell-Derived Neurons Contain a Transcriptional Network. Neurochem Res (2020) 45(7):1711–28. doi: 10.1007/s11064-020-03019-w
136
UpadhyaRMadhuLNAttaluriSGitaíDLGPinsonMRKodaliMet al. Extracellular Vesicles From Human iPSC-Derived Neural Stem Cells: miRNA and Protein Signatures, and Anti-Inflammatory and Neurogenic Properties. J Extracell Vesicles (2020) 9(1):1809064. doi: 10.1080/20013078.2020.1809064
137
LiWYZhuQBJinLYYangYXuXYHuXY. Exosomes Derived From Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Protect Neuronal Function Under Ischemic Conditions. Neural Regener Res (2021) 16(10):2064–70. doi: 10.4103/1673-5374.308665
138
DuYLiDHanCWuHXuLZhangMet al. Exosomes From Human-Induced Pluripotent Stem Cell–Derived Mesenchymal Stromal Cells (hiPSC-MSCs) Protect Liver Against Hepatic Ischemia/ Reperfusion Injury via Activating Sphingosine Kinase and Sphingosine-1-Phosphate Signaling Pathway. Cell Physiol Biochem (2017) 43(2):611–25. doi: 10.1159/000480533
139
XiaYLingXHuGZhuQZhangJLiQet al. Small Extracellular Vesicles Secreted by Human iPSC-Derived MSC Enhance Angiogenesis Through Inhibiting STAT3-Dependent Autophagy in Ischemic Stroke. Stem Cell Res Ther (2020) 11(1):313. doi: 10.1186/s13287-020-01834-0
140
GaoRYeTZhuZLiQZhangJYuanJet al. Small Extracellular Vesicles From iPSC-Derived Mesenchymal Stem Cells Ameliorate Tendinopathy Pain by Inhibiting Mast Cell Activation. Nanomed (2022) 17(8):513–29. doi: 10.2217/nnm-2022-0036
141
ZhangJGuanJNiuXHuGGuoSLiQet al. Exosomes Released From Human Induced Pluripotent Stem Cells-Derived MSCs Facilitate Cutaneous Wound Healing by Promoting Collagen Synthesis and Angiogenesis. J Transl Med (2015) 13(1):49. doi: 10.1186/s12967-015-0417-0
142
AdamiakMChengGBobis-WozowiczSZhaoLKedracka-KrokSSamantaAet al. Induced Pluripotent Stem Cell (iPSC)–Derived Extracellular Vesicles Are Safer and More Effective for Cardiac Repair Than iPSCs. Circ Res (2018) 122(2):296–309. doi: 10.1161/CIRCRESAHA.117.311769
143
LiuSMahairakiVBaiHDingZLiJWitwerKWet al. Highly Purified Human Extracellular Vesicles Produced by Stem Cells Alleviate Aging Cellular Phenotypes of Senescent Human Cells. Stem Cells (2019) 37(6):779–90. doi: 10.1002/stem.2996
144
KarnasESekuła-StryjewskaMKmiotek-WasylewskaKBobis-WozowiczSRyszawyDSarnaMet al. Extracellular Vesicles From Human iPSCs Enhance Reconstitution Capacity of Cord Blood-Derived Hematopoietic Stem and Progenitor Cells. Leukemia (2021) 35(10):2964–77. doi: 10.1038/s41375-021-01325-y
145
de AbreuRCFernandesHda Costa MartinsPASahooSEmanueliCFerreiraL. Native and Bioengineered Extracellular Vesicles for Cardiovascular Therapeutics. Nat Rev Cardiol (2020) 17(11):685–97. doi: 10.1038/s41569-020-0389-5
146
ColaoILCortelingRBracewellDWallI. Manufacturing Exosomes: A Promising Therapeutic Platform. Trends Mol Med (2018) 24(3):242–56. doi: 10.1016/j.molmed.2018.01.006
147
ManKBrunetMYFernandez-RhodesMWilliamsSHeaneyLMGethingsLAet al. Epigenetic Reprogramming Enhances the Therapeutic Efficacy of Osteoblast-Derived Extracellular Vesicles to Promote Human Bone Marrow Stem Cell Osteogenic Differentiation. J Extracell Vesicles (2021) 10(9):e12118. doi: 10.1002/jev2.12118
148
HuangRQinCWangJHuYZhengGQiuGet al. Differential Effects of Extracellular Vesicles From Aging and Young Mesenchymal Stem Cells in Acute Lung Injury. Aging. (2019) 11(18):7996–8014. doi: 10.18632/aging.102314
149
DorronsoroASantiagoFEGrassiDZhangTLaiRCMcGowanSJet al. Mesenchymal Stem Cell-Derived Extracellular Vesicles Reduce Senescence and Extend Health Span in Mouse Models of Aging. Aging Cell (2021) 20(4):e13337. doi: 10.1111/acel.13337
150
KimHLeeMJBaeEHRyuJSKaurGKimHJet al. Comprehensive Molecular Profiles of Functionally Effective MSC-Derived Extracellular Vesicles in Immunomodulation. Mol Ther (2020) 28(7):1628–44. doi: 10.1016/j.ymthe.2020.04.020
151
Fafián-LaboraJLesende-RodriguezIFernández-PernasPSangiao-AlvarellosSMonserratLArntzOJet al. Effect of Age on Pro-Inflammatory miRNAs Contained in Mesenchymal Stem Cell-Derived Extracellular Vesicles. Sci Rep (2017) 7(1):1–12. doi: 10.1038/srep43923
152
KimSLeeSKKimHKimTM. Exosomes Secreted From Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Accelerate Skin Cell Proliferation. Int J Mol Sci (2018) 19(10):3119. doi: 10.3390/ijms19103119
153
ZhuYWangYZhaoBNiuXHuBLiQet al. Comparison of Exosomes Secreted by Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells and Synovial Membrane-Derived Mesenchymal Stem Cells for the Treatment of Osteoarthritis. Stem Cell Res Ther (2017) 8(1):1–11. doi: 10.1186/s13287-017-0510-9
154
SkamagkiMZhangCRossCAAnanthanarayananALiuZMuQet al. RNA Exosome Complex-Mediated Control of Redox Status in Pluripotent Stem Cells. Stem Cell Rep (2017) 9(4):1053–61. doi: 10.1016/j.stemcr.2017.08.024
155
XinHKatakowskiMWangFQianJYLiuXSAliMMet al. MicroRNA Cluster miR-17-92 Cluster in Exosomes Enhance Neuroplasticity and Functional Recovery After Stroke in Rats. Stroke (2017) 48(3):747–53. doi: 10.1161/STROKEAHA.116.015204
156
XinHLiYLiuZWangXShangXCuiYet al. MiR-133b Promotes Neural Plasticity and Functional Recovery After Treatment of Stroke With Multipotent Mesenchymal Stromal Cells in Rats via Transfer of Exosome-Enriched Extracellular Particles. Stem Cells Dayt Ohio (2013) 31(12):2737–46. doi: 10.1002/stem.1409
157
ShenHYaoXLiHLiXZhangTSunQet al. Role of Exosomes Derived From miR-133b Modified MSCs in an Experimental Rat Model of Intracerebral Hemorrhage. J Mol Neurosci MN (2018) 64(3):421–30. doi: 10.1007/s12031-018-1041-2
158
HanDWangKZhangTGaoGCXuH. Natural Killer Cell-Derived Exosome-Entrapped Paclitaxel can Enhance its Anti-Tumor Effect. Eur Rev Med Pharmacol Sci (2020) 24:5703–13. doi: 10.26355/eurrev_202005_21362
159
BökerKOLemus-DiazNFerreiraRRSchillerLSchneiderSGruberJ. The Impact of the CD9 Tetraspanin on Lentivirus Infectivity and Exosome Secretion. Mol Ther (2018) 26(2):634–47. doi: 10.1016/j.ymthe.2017.11.008
160
KimSKimTM. Generation of Mesenchymal Stem-Like Cells for Producing Extracellular Vesicles. World J Stem Cells (2019) 11(5):270–80. doi: 10.4252/wjsc.v11.i5.270
161
HarasztiRAMillerRStoppatoMSereYYColesADidiotMCet al. Exosomes Produced From 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity. Mol Ther (2018) 26(12):2838–47. doi: 10.1016/j.ymthe.2018.09.015
162
TristanCAOrmanogluPSlameckaJMalleyCChuPHJovanovicVMet al. Robotic High-Throughput Biomanufacturing and Functional Differentiation of Human Pluripotent Stem Cells. Stem Cell Rep (2021) 16(12):3076–92. doi: 10.1016/j.stemcr.2021.11.004
163
SaetersmoenMLHammerQValamehrBKaufmanDSMalmbergKJ. Off-The-Shelf Cell Therapy With Induced Pluripotent Stem Cell-Derived Natural Killer Cells. Semin Immunopathol (2019) 41(1):59–68. doi: 10.1007/s00281-018-0721-x
Summary
Keywords
natural killer cells, extracellular vesicles, exosomes, induced pluripotent stem cells, manufacturing, genome engineering, immunotherapy, cancer
Citation
Boyd-Gibbins N, Karagiannis P, Hwang DW and Kim S-I (2022) iPSCs in NK Cell Manufacturing and NKEV Development. Front. Immunol. 13:890894. doi: 10.3389/fimmu.2022.890894
Received
07 March 2022
Accepted
03 June 2022
Published
08 July 2022
Volume
13 - 2022
Edited by
Evelyn Ullrich, Goethe University Frankfurt, Germany
Reviewed by
Daniela Pende, San Martino Hospital (IRCCS), Italy; Frank M. Cichocki, University of Minnesota Twin Cities, United States
Updates
Copyright
© 2022 Boyd-Gibbins, Karagiannis, Hwang and Kim.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shin-Il Kim, sikim@therabest.co.kr
This article was submitted to NK and Innate Lymphoid Cell Biology, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.